港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

轩竹生物-B

63.600

-0.350-0.55%

成交量：33.68万

成交额：2,124.75万

市值：329.41亿

市盈率：-47.11

高：63.900

开：63.900

低：62.500

收：63.950

52周最高：72.000

52周最低：23.820

股本：5.18亿

香港流通股本：1.61亿

量比：0.99

换手率：0.21%

股息：- -

股息率：- -

每股收益(LYR):-1.350

净资产收益率：--

总资产收益率：--

市净率：35.62

市盈率(LYR):-47.11

市销率: 942.80

数据加载中...

总览公司新闻资讯公告

市值超130亿，山东富豪收获一个IPO

四环医药(00460.HK)：轩竹生物10月15日在联交所主板上市

H拆H：开盘涨超153%，轩竹生物今日港股上市

开盘涨超153%！轩竹生物登陆港交所依旧难掩“造血”焦虑

21世纪经济报道

“双轮驱动+商业化三驾马车”，轩竹生物-B(02575)剑指港市Biopharma新标杆

轩竹生物登陆港交所开盘平开，总市值156亿港元

异动解读 | 轩竹生物-B上市首日大涨163.79%，创新药管线引发投资热潮

新股首日｜轩竹生物-B首挂高开近154%，中签一手赚8930港元

老虎资讯综合

轩竹生物-B股票香港上市首日预计以每股29.46港元开盘发行价为每股11.60港元

从Biotech到Biopharma的跨越：轩竹生物-B（2575.HK）以“三轮驱动”构建国产创新药核心竞争力

智通港股投资日志|10月15日

轩竹生物-B港股暗盘现涨超158%，报30.00港元

每日经济新闻

港股四环医药旗下轩竹生物-B暗盘涨超140%，成交量超250万手，振幅达100.86%

老虎暗盘 | 轩竹生物-B涨超200%，中签一手赚约11700港元

老虎资讯综合

轩竹生物XZP - 7797 - H1片启动Ⅰ期临床适应症为晚期实体瘤

轩竹生物将在港上市：募资净额约7亿港元，曾拟在A股募资约25亿元

【新股IPO】国元国际指轩竹生物(02575)管线有一定的竞争力

港股IPO动态：今日长风药业上市

港股异动 | 四环医药(00460)再涨超4% 轩竹生物今起招股公司旗下“冻妍”获批上市

BRIEF-中国生物制药公司轩竹生物拟在香港IPO筹7.8亿港元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02575/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"轩竹生物-B","latestPrice":63.6,"timestamp":1763366893772,"preClose":63.95,"halted":0,"volume":336804,"delay":0,"floatShares":160701996,"shares":517947790,"eps":-1.3500890971603585,"marketStatus":"已收盘","change":-0.35,"latestTime":"11-17 16:08:13","open":63.9,"high":63.9,"low":62.5,"amount":21247494,"amplitude":0.021892,"askPrice":63.65,"askSize":2500,"bidPrice":63.2,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-1.3499240022776209,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":5,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":63.95,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":0.994732,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":160701996,"roa":"--","roe":"--","lyrEps":-1.350089,"volumeRatio":0.994732,"shares":517947790,"dividePrice":0,"high":63.9,"amplitude":0.021892,"preClose":63.95,"low":62.5,"week52Low":23.82,"pbRate":"35.62","psRate":"942.80","week52High":72,"institutionHeld":0,"latestPrice":63.6,"committee":-0.666667,"eps":-1.3500890971603585,"divideRate":0,"volume":336804,"delay":0,"ttmEps":-1.3499240022776209,"open":63.9,"prevYearClose":11.6,"prevWeekClose":63.95,"prevMonthClose":63.6,"prevQuarterClose":11.6,"fiveDayClose":66.2,"twentyDayClose":33.9,"sixtyDayClose":11.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2025-11-14","current":-46.796344,"percent":0.428571,"low":-59.374256,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"high":-22.444691,"avg":-48.666426,"sd":11.257814,"marketCap":33122761170},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170}],"updateTime":1763353038723},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575058271","title":"市值超130亿，山东富豪收获一个IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2575058271","media":"猎云网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575058271?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 12:55","pubTimestamp":1760504132,"startTime":"0","endTime":"0","summary":"每股发售价11.6港元，开盘涨153.97%至29.46港元；截至午间休盘，每股涨128.45%至26.5港元，总市值137.26亿。截至目前，四环医药总市值已超130亿港元，截至最后实际可行日期，轩竹生物有超过十种药物资产在积极开发中，涵盖消化系统疾病、肿瘤和非酒精性脂肪性肝炎。截至最后实际可行日期，轩竹生物有三项NDA批准资产，一个药物项目处于NDA注册阶段，一个药物项目处于III期临床试验阶段，四个药物项目处于I期临床试验阶段，五个已获IND批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251015125550972ee2a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251015125550972ee2a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","00460"],"gpt_icon":1},{"id":"2575271662","title":"四环医药(00460.HK)：轩竹生物10月15日在联交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2575271662","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575271662?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 12:37","pubTimestamp":1760503021,"startTime":"0","endTime":"0","summary":"格隆汇10月15日丨四环医药(00460.HK)宣布，关建议分拆及公司附属公司轩竹生物于联交所主板独立上市。于全球发售完成后，分拆公司于2025年10月15日在联交所主板上市，而分拆公司H股于2025年10月15日上午九时正开始于联交所主板买卖。\r\n\r\n　　\r\n\r\n　　【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251015/31707892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02575","BK1515","BK1593","BK1191","BK1600","00460"],"gpt_icon":0},{"id":"2575276096","title":"H拆H：开盘涨超153%，轩竹生物今日港股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2575276096","media":"药时空","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575276096?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 11:51","pubTimestamp":1760500287,"startTime":"0","endTime":"0","summary":"今日，轩竹生物正式港股上市，开盘涨超153%。轩竹生物作为背靠四环医药的“创二代”，其港股IPO无疑成为市场焦点。财务数据显示，轩竹生物目前仍未扭亏。2023年、2024年及2025年6月30日止六个月，轩竹生物分别实现收入2.9万元、3009.4万元及1789.3万元，同期亏损总额分别为3.01亿元、5.56亿元及1.11亿元，累计亏损超9亿元。2022年，轩竹生物首次申报科创板IPO，并于2024年5月撤回申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251015115659972ecd17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"76d655817d1103c0c2b7ce930c1c9f56","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251015115659972ecd17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","00460","BK1515","BK1191","02575","BK1600"],"gpt_icon":1},{"id":"2575278297","title":"开盘涨超153%！轩竹生物登陆港交所 依旧难掩“造血”焦虑","url":"https://stock-news.laohu8.com/highlight/detail?id=2575278297","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575278297?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 10:25","pubTimestamp":1760495129,"startTime":"0","endTime":"0","summary":"【开盘涨超153%！轩竹生物登陆港交所 依旧难掩“造血”焦虑】对于当前生物医药企业赴港上市热潮，香港生产力促进局首席数码总监及内地业务首席执行官黎少斌在接受记者采访时表示，“内地药企进入香港市场的过程中，两地有望在产品研发、市场战略、资金运作等领域深化合作。除融资优势外，香港在生命健康领域拥有世界领先的科研基础设施与成熟监管环境，将为内地企业布局国际市场提供重要支撑。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"eastmoney_highlight","url":"http://finance.eastmoney.com/news/1354,202510153534636140.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"ada851f5018bec7a50016fdc1e8c02c4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202510153534636140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["02575"],"gpt_icon":1},{"id":"2575220514","title":"“双轮驱动+商业化三驾马车”，轩竹生物-B(02575)剑指港市Biopharma新标杆","url":"https://stock-news.laohu8.com/highlight/detail?id=2575220514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575220514?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 09:42","pubTimestamp":1760492543,"startTime":"0","endTime":"0","summary":"上市当日，轩竹生物股价早盘冲高至最高31港元，涨幅高达167%。凭借自身消化+肿瘤双轮驱动下形成的产品端“三驾马车”，轩竹生物在国内填补临床空白的优势的同时，也在依托自身强劲的商业化推进能力，持续开辟更广阔的适应症市场，彰显公司Biopharma的底色。目前公司正加速差异化创新，Biopharma价值获进一步验证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1355141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575"],"gpt_icon":1},{"id":"2575227735","title":"轩竹生物登陆港交所开盘平开，总市值156亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575227735","media":"瑞财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575227735?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 09:36","pubTimestamp":1760492192,"startTime":"0","endTime":"0","summary":"10月15日，轩竹生物-B(02575)在港交所挂牌上市，独家保荐人为中金公司，开盘平开，总市值156.01亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101509364194c9c16c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101509364194c9c16c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"1131136011","title":"异动解读 | 轩竹生物-B上市首日大涨163.79%，创新药管线引发投资热潮","url":"https://stock-news.laohu8.com/highlight/detail?id=1131136011","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131136011?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 09:32","pubTimestamp":1760491949,"startTime":"0","endTime":"0","summary":"轩竹生物-B今日在港交所主板正式挂牌上市，盘中股价大涨163.79%，引发市场广泛关注。该股上市首日表现亮眼，充分反映了投资者对创新生物制药企业的热情。轩竹生物-B此次IPO定价为每股11.60港元，共发行6733.35万股H股。上市首日开盘价为29.46港元，较发行价上涨153.97%，随后继续攀升。分析人士指出，轩竹生物-B的强劲表现不仅反映了公司自身的研发实力和商业化潜力，也体现了投资者对中国生物医药行业整体前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"76d655817d1103c0c2b7ce930c1c9f56","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02575"],"gpt_icon":1},{"id":"2575165792","title":"新股首日｜轩竹生物-B首挂高开近154%，中签一手赚8930港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575165792","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575165792?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 09:25","pubTimestamp":1760491500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)公布配发结果，公司全球发售6733.35万股H股，香港公开发售占10%，国际发售占90%。每股发售价11.6港元，全球发售净筹约7.01亿港元。每手500股，预期H股将于2025年10月15日(星期三)上午九时正(香港时间)开始在联交所买卖。其中，香港公开发售获4,908.33倍认购，国际发售获10.15倍认购。","market":"hk","thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"76d655817d1103c0c2b7ce930c1c9f56","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1355027.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"轩竹生物-B每股发售价11.6港元，香港公开发售获4908.33倍认购","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"1105061473","title":"轩竹生物-B股票香港上市首日预计以每股29.46港元开盘 发行价为每股11.60港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105061473","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105061473?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 09:23","pubTimestamp":1760491407,"startTime":"0","endTime":"0","summary":"轩竹生物-B股票香港上市首日预计以每股29.46港元开盘 发行价为每股11.60港元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"23d0a55dc84f4e13e9ecdb8968b3ef23","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"2575227584","title":"从Biotech到Biopharma的跨越：轩竹生物-B（2575.HK）以“三轮驱动”构建国产创新药核心竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2575227584","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575227584?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 09:21","pubTimestamp":1760491317,"startTime":"0","endTime":"0","summary":"轩竹生物此次港股上市，不仅是公司发展的里程碑，更是其从Biotech向Biopharma转型的“价值重估起点”。","market":"fut","thumbnail":"https://img2.gelonghui.com/b17e2-d966b981-20ff-4967-8590-d40f85d09213.jpg?guru_height=720&guru_width=1280&guru_size=154189","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b17e2-d966b981-20ff-4967-8590-d40f85d09213.jpg?guru_height=720&guru_width=1280&guru_size=154189"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2994657","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1574","BK1161","02575","06978"],"gpt_icon":1},{"id":"2575103432","title":"智通港股投资日志|10月15日","url":"https://stock-news.laohu8.com/highlight/detail?id=2575103432","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575103432?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 00:00","pubTimestamp":1760457602,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2025年10月15日，港股上市公司投资日志如下：    类别 公司  新股活动广和通(招股中)聚水潭(招股中)海西新药(定价日)轩竹生物-B(上市日) 业绩公布日中国来骑哦 股东大会召开日瓦普思瑞元宇宙智升集团控股云南水务华控康泰天臣控股龙皇集团康宁医院健世科技-B中泽丰海纳星空科技 停复牌嘉进投资国际（复牌） 分红派息AEON CREDIT（除净日）上海实业控股（派息日）光","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1355062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","02575","09877"],"gpt_icon":0},{"id":"2575744262","title":"轩竹生物-B港股暗盘现涨超158%，报30.00港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575744262","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575744262?lang=zh_cn&edition=fundamental","pubTime":"2025-10-14 16:38","pubTimestamp":1760431088,"startTime":"0","endTime":"0","summary":"轩竹生物-B港股暗盘现涨超158%，报30.00港元","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510143533650323.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"ada851f5018bec7a50016fdc1e8c02c4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510143533650323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02575"],"gpt_icon":0},{"id":"2575267142","title":"港股四环医药旗下轩竹生物-B暗盘涨超140%，成交量超250万手，振幅达100.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575267142","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575267142?lang=zh_cn&edition=fundamental","pubTime":"2025-10-14 16:27","pubTimestamp":1760430477,"startTime":"0","endTime":"0","summary":"港股 四环医药 旗下轩竹生物-B暗盘涨超140%，成交量超250万手，振幅达100.86%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014164037a6b8a7b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"ada851f5018bec7a50016fdc1e8c02c4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014164037a6b8a7b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00460","02575","BK1515","BK1191","BK1600","BK1593"],"gpt_icon":0},{"id":"1185100446","title":"老虎暗盘 | 轩竹生物-B涨超200%，中签一手赚约11700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185100446","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185100446?lang=zh_cn&edition=fundamental","pubTime":"2025-10-14 16:16","pubTimestamp":1760429760,"startTime":"0","endTime":"0","summary":"轩竹生物-B涨超200%，总市值突破180亿港元！截至最后实际可行日期，公司有超过十种药物资产在积极开发中，涵盖消化系统疾病、肿瘤和NASH。公司推动药物开发的速度及执行力卓越，借此脱颖而出，截至最后实际可行日期已获得共20项IND批准。轩竹生物已经建立一个全面的内部研发平台，作为公司业务的基石和长期增长的动力。通过自主研发和资产对外授权双轨制，公司已迅速将这些候选药物推向市场，并已获得或提交七项NDA。","market":"us","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ada851f5018bec7a50016fdc1e8c02c4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":1},{"id":"2574339934","title":"轩竹生物XZP - 7797 - H1片启动Ⅰ期临床 适应症为晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2574339934","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574339934?lang=zh_cn&edition=fundamental","pubTime":"2025-10-11 12:31","pubTimestamp":1760157060,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，轩竹生物科技股份有限公司/山东轩竹医药科技有限公司的评估XZP - 7797 - H1治疗晚期实体瘤受试者的安全性、耐受性、药代动力学特征和初步疗效的开放、多中心I期临床研究已启动。XZP - 7797 - H1片为化学药物，适应症为晚期实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101112371694c2a6be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101112371694c2a6be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":1},{"id":"2574123546","title":"轩竹生物将在港上市：募资净额约7亿港元，曾拟在A股募资约25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574123546","media":"贝多财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574123546?lang=zh_cn&edition=fundamental","pubTime":"2025-10-10 15:44","pubTimestamp":1760082240,"startTime":"0","endTime":"0","summary":"本次上市，轩竹生物拟定的发售价为每股11.60港元，募资总额约为7.81亿港元，募资净额约为7.01亿港元。据贝多商业&贝多财经了解，轩竹生物曾于2022年在上海证券交易所递交招股书，报考在科创板上市，原计划募资24.70亿元。2023年3月，轩竹生物上会但被暂缓审议。因此，该公司决定寻求H股于港交所上市。四环医药在此前公告中称，上市完成后，轩竹生物将仍为四环医药的附属公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101015461094c18ebb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101015461094c18ebb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00460","02575"],"gpt_icon":1},{"id":"2574822941","title":"【新股IPO】国元国际指轩竹生物(02575)管线有一定的竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2574822941","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574822941?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 13:44","pubTimestamp":1759988675,"startTime":"0","endTime":"0","summary":"针对成人反流性食管炎的III期临床于2025年7月启动。同时，于2025年4月提交联合芳香化酶抑制NDA申请，预计2026年第三季度获批上市。XZP-3621：已获NDA批准，治疗ALK阳性晚期非小细胞肺癌，于2025年8月获批上市，并于2025年第四季度开始商业化。发行后市值为61亿港元，公司管线有一定的竞争力。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/MTFmM2Q2MTRhOWM5YmViYzgzOWMzMDFlOWYzNjEzNTY0MjA2MzIx.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MTFmM2Q2MTRhOWM5YmViYzgzOWMzMDFlOWYzNjEzNTY0MjA2MzIx.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1967478","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":1},{"id":"2573921508","title":"港股IPO动态：今日长风药业上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2573921508","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573921508?lang=zh_cn&edition=fundamental","pubTime":"2025-10-08 06:09","pubTimestamp":1759874999,"startTime":"0","endTime":"0","summary":"格隆汇10月8日｜今日长风药业(2652.HK)上市，轩竹生物-B(2575.HK)申购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100806113394be559b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100806113394be559b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","HSTECH"],"gpt_icon":0},{"id":"2573624330","title":"港股异动 | 四环医药(00460)再涨超4% 轩竹生物今起招股 公司旗下“冻妍”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2573624330","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573624330?lang=zh_cn&edition=fundamental","pubTime":"2025-10-06 14:28","pubTimestamp":1759732136,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药(00460)再涨超4%，截至发稿，涨4.47%，报1.87港元，成交额6651.81万港元。消息面上，轩竹生物于10月6日至10月10日招股，该公司拟全球发售6733.35万股，预期股份将于10月15日在联交所开始买卖。据悉，轩竹生物分拆自四环医药。此外，四环医药旗下渼颜空间自主研发的“注射用透明质酸钠复合溶液——冻妍”近日获得国家药监局三类医疗器械注册证，标志着国内首款含L-肌肽复合溶液水光针正式登陆资本市场视野。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d26aa812aba485e9cce82e67f394d390","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1352374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","YANG","BK1515","BK1593","02575","BK4614","BK1600","00460"],"gpt_icon":0},{"id":"2573647851","title":"BRIEF-中国生物制药公司轩竹生物拟在香港IPO筹7.8亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2573647851","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573647851?lang=zh_cn&edition=fundamental","pubTime":"2025-10-06 09:02","pubTimestamp":1759712526,"startTime":"0","endTime":"0","summary":"BRIEF-中国生物制药公司轩竹生物拟在香港IPO筹7.8亿港元路透香港10月6日 - 中国生物制药公司--轩竹生物科技股份有限公司2575.HK：* 全球发售6,733.35万股H股股份，发售价每股11.6港元，10月6日开始香港公开发售，预期10月15日在联交所开始买卖；独家保荐人为中金公司* 我们有三款核心产品，即KBP-3571（已获NDA批准的治疗消化系统疾病的创新质子泵抑制剂(PPI)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nL3T3VN01K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","02575","BK1600","BK1593","BK1191","BK1515"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":70,"code":"91000000","status":"200"}]}}